🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Squamous Tumors

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC NCT05738434Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Toripalimab (240mg day1, Q3W*3cycle) Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Nimotuzumab, Tegafur, radiotherapy A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: anlotinib + PD-1 inhibitor, PD-1 inhibitor JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410Phase 337 sites📍 Hefei📍 Beijing📍 Beijing Allist Pharmaceuticals, Inc. · Tests: JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites📍 Washington D.C.📍 Athens📍 Lexington Bristol-Myers Squibb · Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors NCT07814248Phase 13 sites📍 Maumee📍 Portland📍 Fairfax TwoStep Therapeutics, Inc. · Tests: TS-104 Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance NCT05692635Phase 21 site📍 Winston-Salem Wake Forest University Health Sciences · Tests: MRI of the Brain, Blood draws, Quality of Life Questionnaires, Gadolinium Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC NCT06100497Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Pembrolizumab, Cisplatin, Paclitaxel-albumin Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer NCT07016724Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: cadonilizumab combined with neoadjuvant radiochemotherapy, neoadjuvant radiochemotherapy Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 Toripalimab Combined With Definitive CCRT for LACC Patients NCT06256224NA1 site📍 Shanghai Ruijin Hospital · Tests: Toripalimab, CCRT Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer NCT05654454Phase 328 sites📍 Arkhangelsk📍 Ivanovo📍 Kaluga Mabscale, LLC · Tests: Bevacizumab, Paclitaxel, Carboplatin Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC NCT07403136Phase 21 site📍 Shanghai Fudan University · Tests: Vebrekotuzumab, PD-1 antibody A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045Phase 21 site📍 Zunyi Second Affiliated Hospital of Zunyi Medical University · Tests: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Con… EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer NCT07518979Phase 21 site📍 Chengdu Jiyan Liu · Tests: Becotatug Vedotin, Pucotenlimab Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726Phase 21 site📍 Chengdu Sichuan University · Tests: Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel, Cisplatin Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06912074Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurre… JMT106 Injection in the Treatment of Advanced Solid Tumors NCT07275073Phase 11 site📍 Zhejiang Shanghai JMT-Bio Inc. · Tests: JMT106 Injection Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688Phase 1, Phase 211 sites📍 San Antonio📍 Tyler📍 Spokane TiumBio Co., Ltd. · Tests: TU2218 + KEYTRUDA® (Pembrolizumab) Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC NCT07038629Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: S1, Iparomlimab, Radiation Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607Phase 298 sites📍 Los Angeles📍 Baltimore📍 New York AstraZeneca · Tests: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy